The federal government sent a reply to the British embassy and the president of the AstraZeneca laboratory accepting the proposal for a cooperation agreement on technological development and Brazil's access to the vaccine for Covid-19. The agreement provides for the purchase of lots of vaccine and technology transfer. If demonstrated to be effective, 100 million doses will be available to the Brazilian population.
The vaccine is developed by the University of Oxford and AstraZeneca, being one of the most promising in the world. In Brazil, the technology will be developed by Fiocruz (Fundação Oswaldo Cruz), foundation of the Ministry of Health. For the executive secretary of the Ministry of Health, Elcio Franco, the bilateral partnership places Brazil in the lead in the development of the vaccine against the coronavirus. "After the agreement, the country reinforces its contribution to the world in the development of a definitive response to the pandemic and reaffirms its commitment to saving lives," said the secretary.
The agreement, when signed, provides for the transfer of formulation technology, packaging and quality control. The legal provision for technological order provided for in Law 10,973, of 2004, and supported by the bidding law, at 8,666, of 1,993 will be used. The secretary of Science, Technology, Innovation and Strategic Inputs, Hélio Angotti Neto, also pointed out that the Ministry of Health monitors 16 studies of clinical trials related to the vaccine of Covid-19 and that the country will request to have even more vaccines if necessary. “In our technical evaluation, we observed that this is one of the vaccines that is in the most advanced process. In this sense, we have advanced in the protection and care of the Brazilian population ”, he reinforced.
The agreement has two stages. It begins with an order in which Brazil also assumes the risks of research. That is, you will be paid for the technology even if you do not have the results of the final clinical trials. In a second phase, if the vaccine proves to be effective and safe, the purchase will be expanded.
In this initial phase, of assumed risk, there will be 30.4 million doses of the vaccine, totaling U $ 127 million, including the costs of transferring Fiocruz's technology and production process, estimated at U $ 30 million. The two batches to be made available to Fiocruz, of 15.2 million doses each, should be delivered in December 2020 and January 2021.
The federal government considers that this risk of research and production is necessary due to the urgency to search for an effective solution for maintaining public health and safety for the resumption of Brazilian growth. Currently, the vaccine is under clinical trial with tests in Rio de Janeiro, São Paulo and, also, Bahia.
For the national secretary of Health Surveillance, of the Ministry of Health, Arnaldo Correia de Medeiros, based on a response to the effectiveness of the tests, it is estimated that at the beginning of next year, a vaccination campaign can already be carried out, already defining the publics. priority, those most vulnerable to Covid-19. “With the vaccine approved, we will have coverage carried out as part of Brazil's expertise in national vaccination campaigns, in this case prioritizing the most vulnerable audiences such as the elderly, people with comorbidities, health professionals, teachers, security professionals, indigenous people, public transport drivers and people deprived of their freedom, ”he said.
If the vaccine is safe and effective and we are registered in Brazil, there will be another 70 million doses, at an estimated value of US $ 2.30 per dose. With the agreement that will be signed, Brazil takes the lead in the development of the vaccine against coronavirus. The initiative, therefore, not only guarantees that the product is available, but will give Brazilian autonomy in production.